Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies

Bhamidipati, Deepak; Subbiah, Vivek

doi:10.1016/j.trecan.2022.11.003

Cited by 9 publications

(2 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomarker-driven therapy has been gaining prominence in the treatment paradigm for CRC, with several regulatory-approved drugs such as larotrectinib for NTRK fusions, pembrolizumab and dostarlimab for dMMR/MSI-H, and selpercatinib for RET fusion 23 . This underscores the pressing need for further clinical trials for drugs targeting ALK fusion in CRC.…”

Section: Discussionmentioning

confidence: 99%

Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis

Li,

Pat Fong,

Zhang

et al. 2024

npj Precis. Onc.

View full text Add to dashboard Cite

Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) is a rare and chemotherapy-refractory subtype that lacks established and effective treatment strategies. Additionally, the efficacy and safety of ALK inhibitors (ALKi) in CRC remain undetermined. Herein, we examined a series of ALK-positive CRC patients who underwent various lines of ALKi treatment. Notably, we detected an ALK 1196M resistance mutation in a CRC patient who received multiple lines of chemotherapy and ALKi treatment. Importantly, we found that Brigatinib and Lorlatinib demonstrated some efficacy in managing this patient, although the observed effectiveness was not as pronounced as in non-small cell lung cancer cases. Furthermore, based on our preliminary analyses, we surmise that ALK-positive CRC patients are likely to exhibit inner resistance to Cetuximab. Taken together, our findings have important implications for the treatment of ALK-positive CRC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis

Li,

Pat Fong,

Zhang

et al. 2024

npj Precis. Onc.

View full text Add to dashboard Cite

show abstract

“…Two drugs (larotrectinib and entretinib) have been approved by the FDA and EMA for the treatment of patients with an NTRK gene fusion in solid tumors. Neutrotrophic tyrosine receptor kinase (NRTK) genes encode tropomyosin receptor kinase (TRK) proteins, and rearrangements can result in somatic NTRK gene fusions, which can cause the uncontrolled growth of tumors [ 66 ]. NTRK gene fusions can be found in only 0.2% of unselected CRC, but with a higher prevalence in patients with RAS/BRAF wild-type and dMMR tumors.…”

Section: Trkmentioning

confidence: 99%

Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies

Tarpgaard,

Winther,

Pfeiffer

2023

Cancers

View full text Add to dashboard Cite

Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).

show abstract

Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

Brozos-Vázquez,

Toledano-Fonseca,

Costa-Fraga

et al. 2024

Cancer Treatment Reviews

View full text Add to dashboard Cite

Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies

Cited by 9 publications

References 81 publications

Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis

Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis

Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies

Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

Contact Info

Product

Resources

About